Publications by authors named "Katy Moore"

Claim this Profile
P
Population pharmacokinetics and exposure-response relationship for temsavir following fostemsavir administration in treatment-experienced HIV patients.
Ridhi Parasrampuria, Nilay Thakkar, Katy Moore, Peter Ackerman, Mindy Magee

Pharmacol Res Perspect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy.
Farzaneh Salem, Dung Nguyen, Mark Bush, Katy P Moore, Jennypher Mudunuru

CPT Pharmacometrics Syst Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1/2K with fostemsavir coadministration based on modeling approaches.
Dung Nguyen, Xiusheng Miao, Kunal Taskar, Mindy Magee, Pete Gorycki, Katy Moore

Pharmacol Res Perspect· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Based Dose Selection of Fostemsavir for Pediatric Populations With Multidrug-Resistant HIV-1 and Relative Bioavailability Assessment in Healthy Adults.
Nilay Thakkar, Mindy Magee, Navin Goyal, Judah Abberbock, Chris Jones, Katy Moore

Clin Pharmacol Drug Dev· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration.
Nneka Nwokolo, Elana Post, A Savannah Mageau, Rimi Shah, Mindy Magee, Katy Moore

HIV Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, Katy P Moore

Br J Clin Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects.
Peter Gorycki, Mindy Magee, Peter Ackerman, Xiusheng Miao, Katy Moore

Xenobiotica· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
Katy Moore, Nilay Thakkar, Mindy Magee, Heather Sevinsky, Blisse Vakkalagadda

Antimicrob Agents Chemother· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
Mary Beth Wire, Mindy Magee, Peter Ackerman, Cyril Llamoso, Katy Moore

HIV Res Clin Pract· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir.
Mindy Magee, Jill Slater, Frank Mannino, Peter Ackerman, Cyril Llamoso, Katy Moore

J Clin Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis.
Chakradhar Lagishetty, Katy Moore, Peter Ackerman, Cyril Llamoso, Mindy Magee

Clin Transl Sci· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Katy Moore, Mindy Magee, Heather Sevinsky, Ming Chang, Susan Lubin

Br J Clin Pharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.
Romina Quercia, Carlo-Federico Perno, Justin Koteff, Katy Moore, Cynthia McCoig

J Acquir Immune Defic Syndr· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical issues in a modeling approach to assessing bioequivalence or PK similarity with presence of sparsely sampled subjects.
Chuanpu Hu, Katy H P Moore, Yong H Kim, Mark E Sale

J Pharmacokinet Pharmacodyn· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteers.
Katy H P Moore, Scott McNeal, Margaret R Britto, Carole Bye, Mark Sale

Clin Ther· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics of intranasal sumatriptan.
Eliane Fuseau, Olivier Petricoul, Katy H P Moore, Andrew Barrow, Tim Ibbotson

Clin Pharmacokinet· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.
Katy H P Moore, Philip T Leese, Scott McNeal, Peter Gray, Stephen O'Quinn

Clin Ther· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis